科技部新聞稿

科技部與經濟部合作攜手嬌生集團楊森藥廠培育臺灣生技之星！

日期：108年12月5日

發稿單位：產學及園區業務司

聯絡人：林明徹科長

電話：02-2737-7212

Email：miclin@nstc.gov.tw

臺灣首次與國際集團楊森大藥廠(Janssen Pharmaceuticals)共同出資與選題，推動「臺灣-楊森計畫」針對癌症議題徵案

 臺灣首次與國際嬌生集團(Johnson & Johnson)集團楊森藥廠(Janssen Pharmaceuticals)共同出資與選題，推動「臺灣-楊森計畫」。針對癌症議題對臺灣的學研單位徵案，遴選具開發成藥品或醫療診斷醫材產品之潛力技術，本次遴選結果記者會由科技部謝達斌次長與經濟部羅達生處長主持，今（5）日於南港雅悅會館進行頒獎。

    本合作案是科技部、經濟部與楊森藥廠(Janssen Pharmaceuticals)共同出資提供學術和研究機構研發獎勵及輔導，不但為科技部年度重要的國際產學合作計畫，也是我國生醫領域研究成果邁向國際化的里程碑。

楊森藥廠(Janssen Pharmaceuticals)是國際知名大藥廠，致力研發並行銷創新、高品質的藥物，包括癌症、免疫、抗感染疾病、精神科、肺動脈高壓用藥…等多種領域之用藥。臺灣嬌生公司旗下之楊森子公司並榮獲「2009年天下企業公民獎」。

    今(108)年聚焦在肺癌及大腸直腸癌議題徵選，由法人組工研院生醫所鄭平福博士團隊及學研組臺灣大學蔡幸真教授團隊和台北醫學大學林榮俊教授團隊獲獎。

    科技部、經濟部與國際大廠楊森藥廠攜手進行「臺灣- 楊森合作計畫」，今(108)年聚焦在肺癌及大腸直腸癌之醫療議題徵選研究計畫，法人組部份由工研院生醫所鄭平福博士團隊獲獎，楊森藥廠將提供此計畫三年50萬美元的研究經費，並由經濟部相對提撥經費補助。學研組則由臺灣大學蔡幸真教授團隊，研究開發早期肺癌之表觀遺傳標記血液檢測，以及台北醫學大學林榮俊教授團隊，研究腸道總微生物組定序應用於建構大腸直腸癌高風險族群之體外篩檢平台獲獎，團隊將可獲得由科技部提供之6萬美元及4萬美元的獎金，並由楊森大藥廠提供為期6個月的一對一技術研發輔導。

科技部與經濟部攜手楊森藥廠共同培育符合國際醫療市場需求的優秀研究團隊，也開啟了國際合作創新模式

    科技部謝達斌次長指出，根據「世界經濟論壇」（WEF）2019年全球競爭力報告（The Global Competitiveness Report 2019），台灣在「創新能力」指標方面繼續名列前茅，排名全球第4、亞太第一，榮登全球前四大創新國家之一；而根據CEO WORLD magazine 醫療保健指標(Health Care Index)，在全球89個國家當中，臺灣的醫療保健指數更是排名世界第一。 臺灣具有全球最好的醫療系統、優異的醫學技術，更有頂尖的研究人才，因此能吸引國際生技醫藥大廠的關注，科技部與經濟部攜手楊森藥廠(Janssen Pharmaceuticals)共同培育符合國際醫療市場需求的優秀研究團隊，鼓勵他們的技術商業化，也開啟了國際合作創新模式。

Press Release

December 5, 2019

MOST, MOEA Team Up with Janssen to Foster Bio-Star in Taiwan

The Collaboration Project between the Ministry of Science and Technology (MOST) Taiwan and Janssen Biotech, Inc. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson), the first academia-industry collaboration that Taiwan has forged with a global pharmaceutical company, is bringing funding and focus to specific disease areas. Zooming in on cancer research, it solicited project proposals from Taiwan’s academic and research institutions in a bid to identify technologies that hold promise for development into drugs or medical and diagnostic equipment. Funds jointly offered by the Ministry of Science and Technology (MOST), Ministry of Economic Affairs (MOEA), and Janssen will be distributed to academic and research institutions as R&D grants and assistance to advance projects of mutual interest. For the MOST, this project is an important international academia-industry collaboration for the year. But equally significant is its marking a milestone in Taiwan’s bringing R&D achievements in biotech to the international community. 

Janssen, an international pharmaceutical company, is committed to the discovery and development of medicines for the treatment of some of the world’s most complex diseases, like cancer. Based on this commitment, Janssen’s Taiwan affiliate was a recipient of Common Wealth Magazine’s 2009 Excellence in Corporate Social Responsibility Awards.

In 2019, the Taiwan-Janssen Project focused on research projects geared toward treating lung and colorectal cancer. R&D proposals from a non-profit division and two academic/research divisions were rated as worthy. The non-profit division, represented by Dr. Ping-fu Cheng and his team from the Biomedical Technology and Device Research Laboratories at the Industrial Technology Research Institute (ITRI), were awarded from Janssen a three-year grant of US$500,000, with an equivalent amount to be appropriated by the MOEA. Of the top three applicants from academic/research division, Assistant Prof. Hsing-chen Tsai and her team from National Taiwan University will secure a MOST grant of US$60,000 for developing blood tests to identify epigenetic markers that could act as early signs of cancer. Meanwhile, Prof. Jung-chun Lin and his team from Taipei Medical University will receive a MOST grant of US$40,000 for developing ways to apply intestinal metagenomic sequencing to the development of an in vitro screening platform meant for people most vulnerable to develop colorectal cancer. Janssen will provide both teams with one-on-one R&D guidance for six months.

MOST Deputy Minister Dar-Bin Shieh cites the World Economic Forum’s (WEF) Global Competitiveness Report 2019 that continued to rank Taiwan among global leaders in terms of innovation capability: No. 4 worldwide and No. 1 in the Asia Pacific. Moreover, the WEF rated Taiwan as one of the world’s four “super innovators.” Using its Health Care Index to gauge 89 countries, CEOWORLD Magazine also granted Taiwan the honor of No. 1. Taiwan has attracted the attention of leading global biotech and pharmaceutical companies because it owns the world’s best medical care system, excellent medical technologies, and top-notch R&D professionals. The MOST and MOEA joined forces with Janssen to foster research teams aimed at meeting the needs of the global medical care market by providing incentives to bring technologies to market and creating a process and model for cross-border collaboration to drive innovation. 

Media Contact

Min-Cheh Lin

Section Chief

Department of Academia-Industry Collaboration and Science Park Affairs,

Ministry of Science and Technology (MOST)

Tel : 886-2-2737-7212

E-mail: miclin@nstc.gov.tw